There are no approved vaccines for HSV, and GSK’s decision to stop developing ... an investigational vaccine for herpes ...

GSK has abandoned its clinical-stage vaccine for herpes simplex virus (HSV) after a disappointing phase 1/2 trial, ceding the ground to mRNA shots in development at Moderna and BioNTech.

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

buying a pneumococcal vaccine candidate that is aiming to break into a market that for years has been dominated by Pfizer's Prevnar franchise. GSK said it is paying $2.1 billion upfront for ...

Symptomatic HSV-2 infection is also associated with an ... and therapeutics that reduce severity and viral load. Another company, GSK, completed a vaccine trial in September 2024, but the vaccine ...

GSK is also working with SK Bioscience on a phase 1/2 study for a vaccine based on self-assembling nanoparticle technology developed by the University of Washington, with funding from CEPI and the ...

Two earlier trials demonstrated that a vaccine based on the HSV-2 glycoprotein D subunit (gD-2) was effective in protecting HSV-1/HSV-2-seronegative women whose sexual partners had recurrent HSV ...

GSK blames political and regulatory pressures ... with Zhifei now set to purchase 21.6bn yuan ($2.97bn) worth of the vaccine over six years. The revision follows a sharp downturn in China ...

Get discount on Purchase report @ Questions Answered by the Report: (1) Which are the dominant players of the Herpes Simplex Virus (Hsv) Vaccines Market? (2) What will be the size of the Herpes ...